Akero Therapeutics (NASDAQ:AKRO)’s share price rose 8.8% on Thursday . The company traded as high as $18.85 and last traded at $18.37, approximately 153,550 shares changed hands during mid-day trading. An increase of 15% from the average daily volume of 133,204 shares. The stock had previously closed at $16.89.

In other news, Director Seth Loring Harrison bought 900,000 shares of Akero Therapeutics stock in a transaction that occurred on Monday, June 24th. The shares were purchased at an average price of $16.00 per share, for a total transaction of $14,400,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Global Strategic Fund I. Venbio bought 250,000 shares of Akero Therapeutics stock in a transaction that occurred on Monday, June 24th. The stock was purchased at an average price of $16.00 per share, for a total transaction of $4,000,000.00. The disclosure for this purchase can be found here.

About Akero Therapeutics (NASDAQ:AKRO)

Akero Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development and commercialization of transformative treatments for serious metabolic diseases with high unmet medical need. Its lead product candidate is AKR-001, which completed Phase Ib clinical trial for the treatment of non-alcoholic steatohepatitis disease.

Recommended Story: What is a conference call?

Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.